ECSP045278A - Compuestos de oxo-azabicíclicos - Google Patents
Compuestos de oxo-azabicíclicosInfo
- Publication number
- ECSP045278A ECSP045278A EC2004005278A ECSP045278A ECSP045278A EC SP045278 A ECSP045278 A EC SP045278A EC 2004005278 A EC2004005278 A EC 2004005278A EC SP045278 A ECSP045278 A EC SP045278A EC SP045278 A ECSP045278 A EC SP045278A
- Authority
- EC
- Ecuador
- Prior art keywords
- group
- inclusive
- integer
- alkyl
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un compuesto seleccionado de aquellos de la fórmula (I): en donde:X1, X2 y X3 representan N o -CR3 en donde R3 es lo descrito en la memoria descriptiva,· G1 representa un grupo seleccionado de aquellos de las fórmulas (i/a) e (i/b): en donde R4, R5, y R6 son lo definido anteriormente, · G2 representa un grupo seleccionado de enlace triple de carbono-carbono, -CH=C=CH-, C=O, C=S, S(O)n1 en donde n1 representa un número entero de 0 a 2 inclusive, y un grupo de la fórmula (i/c): en donde Y1 representa O, S, -NH o -N alquilo e Y2 representa O, S, -NH o -N alquilo,· n es un número entero de 0 a 6 inclusive, y m es un número entero de 0 a 7 inclusive,· Z1 representa -CR9R10, en donde R9 y R10 son lo definido en la memoria descriptiva,· A representa un sistema de anillo,· R1 representa un grupo seleccionado de H, alquilo, alquenilo, alquinilo, optativamente sustituido y el grupo de la fórmula (i/d): en donde p, Z2, B, q y G2 son lo definido en la memoria descriptivay optativamente, sus isómeros ópticos, N-óxidos y sales de ellos con el ácido o base farmacéuticamente aceptable, y productos medicinales que contienen los mismos son útiles como inhibidores específicos de la metaloproteasa de la matriz de tipo 13.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2002/003240 WO2003076416A1 (en) | 2002-03-08 | 2002-03-08 | Oxo azabicyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045278A true ECSP045278A (es) | 2004-10-26 |
Family
ID=27798761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005278A ECSP045278A (es) | 2002-03-08 | 2004-09-03 | Compuestos de oxo-azabicíclicos |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1492775A2 (es) |
| JP (1) | JP2005526070A (es) |
| KR (1) | KR20040095270A (es) |
| CN (1) | CN1738806A (es) |
| AP (1) | AP2004003125A0 (es) |
| AR (1) | AR039562A1 (es) |
| AU (2) | AU2002249275A1 (es) |
| BR (1) | BR0308280A (es) |
| CA (1) | CA2478706A1 (es) |
| CO (1) | CO5601020A2 (es) |
| EA (1) | EA200401053A1 (es) |
| EC (1) | ECSP045278A (es) |
| IL (1) | IL163818A0 (es) |
| IS (1) | IS7414A (es) |
| MA (1) | MA27183A1 (es) |
| MX (1) | MXPA04008681A (es) |
| NO (1) | NO20044041L (es) |
| OA (1) | OA12782A (es) |
| PA (1) | PA8568501A1 (es) |
| PE (1) | PE20031018A1 (es) |
| PL (1) | PL372622A1 (es) |
| SV (1) | SV2003001495A (es) |
| TN (1) | TNSN04169A1 (es) |
| UY (1) | UY27700A1 (es) |
| WO (2) | WO2003076416A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| WO2004014909A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| EP1537098A1 (en) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company LLC | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| WO2004014866A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| BR0313384A (pt) | 2002-08-13 | 2005-07-12 | Warner Lambert Co | Derivados de cromona como inibidores de metaloproteinases de matriz |
| AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| AU2003250471A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
| WO2004014384A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
| DE10360835A1 (de) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
| AU2005238386A1 (en) * | 2004-04-30 | 2005-11-10 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof as an MMP-13 inhibitor |
| CA2568756A1 (en) * | 2004-06-15 | 2005-12-29 | Astrazeneca Ab | Substituted quinazolones as anti-cancer agents |
| KR20090057416A (ko) | 2006-10-05 | 2009-06-05 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 스테아로일 ＣｏＡ 탈포화효소 억제제로서 사용하기 위한, 바이시클릭 질소 함유 헤테로시클릭 화합물 |
| WO2012052451A1 (en) | 2010-10-18 | 2012-04-26 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
| CN103524431B (zh) * | 2013-09-24 | 2016-01-13 | 西安交通大学 | 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用 |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| CA2996857C (en) | 2015-09-23 | 2024-05-21 | Janssen Pharmaceutica Nv | Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer |
| EP3353164B1 (en) | 2015-09-23 | 2021-11-03 | Janssen Pharmaceutica, N.V. | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| FR3046793B1 (fr) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9714222A (pt) * | 1996-12-17 | 2000-04-18 | Du Pont | Método para o controle de doenças de plantas |
| PA8539301A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
| PA8539401A1 (es) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
-
2002
- 2002-03-08 AU AU2002249275A patent/AU2002249275A1/en not_active Abandoned
- 2002-03-08 WO PCT/EP2002/003240 patent/WO2003076416A1/en not_active Ceased
-
2003
- 2003-03-04 SV SV2003001495A patent/SV2003001495A/es not_active Application Discontinuation
- 2003-03-06 IL IL16381803A patent/IL163818A0/xx unknown
- 2003-03-06 EA EA200401053A patent/EA200401053A1/ru unknown
- 2003-03-06 BR BR0308280-6A patent/BR0308280A/pt not_active IP Right Cessation
- 2003-03-06 JP JP2003574636A patent/JP2005526070A/ja not_active Withdrawn
- 2003-03-06 PA PA20038568501A patent/PA8568501A1/es unknown
- 2003-03-06 AP APAP/P/2004/003125A patent/AP2004003125A0/en unknown
- 2003-03-06 WO PCT/EP2003/002277 patent/WO2003076417A2/en not_active Ceased
- 2003-03-06 CN CNA038048752A patent/CN1738806A/zh active Pending
- 2003-03-06 EP EP03708181A patent/EP1492775A2/en not_active Withdrawn
- 2003-03-06 OA OA1200400234A patent/OA12782A/en unknown
- 2003-03-06 PL PL03372622A patent/PL372622A1/xx not_active Application Discontinuation
- 2003-03-06 MX MXPA04008681A patent/MXPA04008681A/es unknown
- 2003-03-06 AR ARP030100749A patent/AR039562A1/es not_active Application Discontinuation
- 2003-03-06 UY UY27700A patent/UY27700A1/es not_active Application Discontinuation
- 2003-03-06 AU AU2003212307A patent/AU2003212307A1/en not_active Abandoned
- 2003-03-06 KR KR10-2004-7013994A patent/KR20040095270A/ko not_active Ceased
- 2003-03-06 PE PE2003000218A patent/PE20031018A1/es not_active Application Discontinuation
- 2003-03-06 CA CA002478706A patent/CA2478706A1/en not_active Abandoned
-
2004
- 2004-08-19 IS IS7414A patent/IS7414A/is unknown
- 2004-08-25 CO CO04082792A patent/CO5601020A2/es not_active Application Discontinuation
- 2004-08-31 MA MA27842A patent/MA27183A1/fr unknown
- 2004-09-03 TN TNP2004000169A patent/TNSN04169A1/fr unknown
- 2004-09-03 EC EC2004005278A patent/ECSP045278A/es unknown
- 2004-09-24 NO NO20044041A patent/NO20044041L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003076416A1 (en) | 2003-09-18 |
| UY27700A1 (es) | 2003-10-31 |
| IL163818A0 (en) | 2005-12-18 |
| AP2004003125A0 (en) | 2004-09-30 |
| EP1492775A2 (en) | 2005-01-05 |
| AU2003212307A1 (en) | 2003-09-22 |
| PA8568501A1 (es) | 2003-12-19 |
| OA12782A (en) | 2006-07-10 |
| NO20044041L (no) | 2004-10-07 |
| EA200401053A1 (ru) | 2005-04-28 |
| CN1738806A (zh) | 2006-02-22 |
| WO2003076417A2 (en) | 2003-09-18 |
| AR039562A1 (es) | 2005-02-23 |
| BR0308280A (pt) | 2004-12-28 |
| KR20040095270A (ko) | 2004-11-12 |
| SV2003001495A (es) | 2003-11-04 |
| CA2478706A1 (en) | 2003-09-18 |
| TNSN04169A1 (fr) | 2007-03-12 |
| PL372622A1 (en) | 2005-07-25 |
| IS7414A (is) | 2004-08-19 |
| MXPA04008681A (es) | 2004-12-06 |
| MA27183A1 (fr) | 2005-01-03 |
| CO5601020A2 (es) | 2006-01-31 |
| AU2002249275A1 (en) | 2003-09-22 |
| WO2003076417A3 (en) | 2003-11-13 |
| PE20031018A1 (es) | 2004-01-09 |
| JP2005526070A (ja) | 2005-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP045278A (es) | Compuestos de oxo-azabicíclicos | |
| ES2190396T3 (es) | Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| PA8582801A1 (es) | Nuevos derivados espirotricíclicos y su uso como inhibidores de la fosfodiesterasa | |
| PE20050012A1 (es) | Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2 | |
| ECSP034460A (es) | Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos | |
| AR245447A1 (es) | Procedimiento para preparar derivados de 2,4-diamino-5-(biciclo-sustituido)metilpirimidinas. | |
| AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
| ES2137998T3 (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos. | |
| AR026173A1 (es) | Inhibidores de neuraminidasas. | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| EA200300044A1 (ru) | Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции | |
| AR027335A1 (es) | Compuestos de piperidina-4-sulfonamida, proceso de preparacion de los mismos, y composiciones farmaceuticas que los contienen | |
| ES2183492T3 (es) | Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| ES2114721T3 (es) | Procedimiento para preparar intermedios derivados del acido benzoico y agentes farmaceuticos benzotiofenos. | |
| CO5590934A2 (es) | Procedimiento de preparacion de derivados de equinocandina | |
| ES2153019T3 (es) | Derivados de benzo-dioxano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| AR027112A1 (es) | Derivados de piperazina sustituidos, su preparacion, su empleo como medicamentos | |
| ES2153457T3 (es) | Amino-alquil-benzoxazolinonas y benzotiazolinonas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen. | |
| AR029537A1 (es) | Nuevos compuestos de ciclopropano 1,1- y 1,2-disubstituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| MX9603272A (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos. | |
| ES2172376B1 (es) | Nuevos derivados de isoquinoleinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| ES2172023T3 (es) | Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| ES2172294T3 (es) | Nuevos derivados del 1-indanol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| AR037498A1 (es) | Compuesto n-(4-amidino-2,6-difluorobenzil)-1-(2-(3-cloro-5-(difluorometoxi)fenil)-2-hidroxiacetil)azetidina-2-carboxamida y compuesto derivado del mismo, composicion farmaceutica, su uso en la preparacion de un medicamento y rutas sinteticas para su produccion | |
| DOP2003000603A (es) | Compuestos oxo-azabiciclicos |